with U-VANCO (vancomycin hydrochloride)

PreclinicalSmall molecule

TTaipei Veterans General Hospital, Taiwan

with U-VANCO (vancomycin hydrochloride) is one of 3 small molecule programs targeting Spine Surgery. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Spine SurgeryRecruiting

Spine SurgeryPreclinical

Recruiting

Competition

Competitive Landscape

3 competitors in Spine Surgery

#DrugCompanyPhaseTrials

Zanaflex

LLegacy Health System

Phase 3

1 2

Bupivacaine Only

Pacira Pharmaceuticals, Inc

Preclinical

1 3

with U-VANCO (vancomycin hydrochloride)

TTaipei Veterans General Hospital, Taiwan

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Spine Surgery

NCT03883022

Clinical

Trials by Indication[1]

Spine Surgery1 trial

Vancomycin Powder Combined With Autogenous Bone Graft as a Prevention for Post-operative Infection for Spine Surgery

Recruiting·TTaipei Veterans General Hospital, Taiwan·N/A·NCT03883022·400 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for with U-VANCO (vancomycin hydrochloride). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — with U-VANCO (vancomycin hydrochloride) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for with U-VANCO (vancomycin hydrochloride). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Taipei Veterans General Hospital, Taiwan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TTaipei Veterans General Hospital, Taiwan

with U-VANCO (vancomycin hydrochloride)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Spine Surgery1 trial

References

Drug Info

Quick Facts

Related News